Search results
Results from the WOW.Com Content Network
Efinaconazole, sold under the brand name Jublia among others, is a triazole antifungal medication. It is approved for use in the United States, Canada, and Japan as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail).
Onychomycosis in every nail of the right foot. Onycholysis is a loosening of the exposed portion of the nail from the nail bed, usually beginning at the free edge and continuing to the lunula . It is frequently associated with an internal disorder , trauma , infection , nail fungi , allergy to nail enhancement products , or side effects of drugs .
Infected nails often appear thick and distorted in shape, and usually in a yellowish green colour, [4] studies have found Griseofulvin [5] and Itraconazole could be an effective treatment for onychomycosis, however a confirmed effective treatment is unclear. [6] Even though O. canadensis is found in infected nails, it is not always a pathogen.
Onychomycosis occurs in about 10 percent of the adult population, [2] with older people more frequently affected. [2] Males are affected more often than females. [3] Onychomycosis represents about half of nail disease. [2] It was first determined to be the result of a fungal infection in 1853 by Georg Meissner. [6]
The recommended first treatment is periodic partial or complete debridement of the thickening nail plate. Other potential treatments that could be helpful are urea pastes with a 40% or greater concentration, electric drills, and nail avulsion.
Ciclopirox is a medication used for the treatment of moderate onychomycosis of fingernails and toenails, [3] and for the treatment of seborrheic dermatitis. [4] In 2022, it was the 247th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [5] [6]
Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed with a complete clearance rate of 6-7% and partial clearance rate of 23-24% in individuals whose “infection border does not reach the cuticle at the base of the large toenail.” [1] Tavaborole was approved by the US FDA in July ...
[1] [2] In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. [3] It is a prodrug that is converted into ravuconazole. [1] Drugs for Neglected Diseases Initiative (DNDi) and the Japanese pharmaceutical company Eisai found that fosravuconazole works as a treatment for mycetoma, a serious condition.